The use of radiation in this setting to destroy residual cancer has previously been sporadic but more recently has gained widespread acceptance.
This often has the effect of killing off residual cancer cells and is the aim of the treatment. Once this treatment is complete the bone marrow or stem cells can be given via an intravenous drip.
After chemotherapy is completed, the woman may undergo "second-look surgery." Her surgeon will examine her remaining pelvic and abdominal structures for evidence of residual cancer.
About 8-12 months after treatment, patients will need a repeat iodine scan to make sure that there is no residual cancer, and to make sure that the cancer has not come back.
Did individual receive radioactive iodine ablation to destroy residual cancer cells?
Was postoperative radioisotope imaging performed to assess for regional or distant metastases?
Did individual require radiation therapy? Chemotherapy?
Although this procedure is the most sensitive way of detecting residual cancer that remains after chemotherapy, it has no proven impact on patient survival. Its use is restricted to patients being treated in clinical trials.
A physician may follow surgery with a combination of radiation and chemotherapy to kill any residual cancer cells that may be lingering after the surgery. Surgery and its accompanying treatments are a curative process.
[15,22] After surgery to remove the primary tumor and/or the metastases, all patients appeared to be free of residual cancer.
For local recurrence after surgical treatment, all scar planes and reconstructive flaps are excised along with residual cancer. Radiation therapy, chemotherapy, or both may be done but have limited effectiveness.
However, even when all of these criteria are met, microscopic amounts of residual cancer (ie, not visible on imaging studies) can still be present. Growth of these microscopic tumor cells is probably responsible for tumor recurrence at a later date.
PET scans are more accurate than CT scans or other imaging tests for staging lymphomas. PET scans may also help doctors determine how well a patient has responded to treatment, if any residual cancer exists, and if a patient has achieved remission.
The donor lymphocytes, which are T cells, attack and kill residual cancer cells. That is the strategy. Donor lymphocyte infusion has mainly been used to treat relapsed chronic myelogenous leukemia (CML).
infusion is to induce a remission of the cancer by a process called the graft-versus-tumor (GVT) effect. Donor lymphocyte infusion is basically meant to boost the GVT effect. The donor lymphocytes, which are T cells, attack and kill residual cancer ...
VII, Cranial Nerve, Paraganglias, Chromaffin, Parkinson Diseases, Experimental, Periarthritides, Protein 2, Microtubule-Associated, Behavioral Genetics, Blindness, Day, Receptor, Granulocyte-Macrophage Colony-Stimulating Factor, Residual Cancer, ...
 See also: Cancer, Symptom, Surgery, Aging, Radiation therapy
  
|
RSS
